Subscribe free

Intestine and Lower Gastrointestinal Tract ·

Biomarkers for Recurrent Rectal Cancer Outcomes

Identifying molecular biomarkers could enhance patient selection for salvage surgery in locally recurrent rectal cancer, impacting surgical strategies and patient outcomes.

  • Locoregional recurrence rates after surgery ranged from 15% to 52% over 3-5 years.
  • Five-year overall survival rates varied from 22% to 53%.

Surgeons should consider serum biomarkers like CEA and CA19-9, linked to poor survival, for patient risk assessment.

  • Elevated CEA was associated with shorter overall survival in 11 studies.
  • Contemporary biomarkers remain unstudied in this population, indicating a research gap.

Review by Vu JK, Younan E (…) Brown KGM et 7 al. in Ann Surg Oncol

© 2026. The Author(s).

read the whole article in Ann Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Intestine and Lower Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Intestine and Lower Gastrointestinal Tract

The latest stitches

Br J Surg5 Nov 2026

Rectal cancer and liver spread: similar outcomes

Removing the rectal tumor and liver spread in one operation did not clearly raise complications or hurt survival compared with two separate operations, a French national study found.

Lancet4 Nov 2026

Colorectal cancer: shorter chemo, fewer side effects

A Japanese randomized trial found that a 14-day schedule of trifluridine-tipiracil plus bevacizumab keeps patients with metastatic colorectal cancer alive as long as the standard 28-day schedule, with far less toxicity.

All papers in Intestine and Lower Gastrointestinal Tract →